

Please amend the application as follows:

*In the claims:*

Please cancel claims 118-159, 286, 288-290, 293, 294, 296, and 298-301 without prejudice or disclaimer.

Please replace claims 31, 47, 56, 63, 79, 95, 109, 291, 292, 302, 304, and 305 with the following amended claims:

D<sup>1</sup> 31. (Amended) The nucleic acid molecule of claim 24 further comprising a nucleotide sequence heterologous to SEQ ID NO:1.

D<sup>2</sup> 47. (Thrice Amended) The nucleic acid molecule of claim 44 that further comprises a nucleotide sequence heterologous to SEQ ID NO:1.

56. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding the full-length polypeptide encoded by the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810;

D<sup>3</sup> (b) a nucleotide sequence encoding the full-length polypeptide, lacking the N-terminal methionine, which is encoded by the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810;

(c) a nucleotide sequence encoding the mature polypeptide encoded by the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810;

(d) a nucleotide sequence encoding the soluble extracellular domain encoded by the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810, respectively; and

(e) a nucleotide sequence that is the complement of (a), (b), (c), or (d).

D<sup>4</sup> 63. (Amended) The nucleic acid molecule of claim 59 further comprising a nucleotide sequence heterologous to the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810.

D5 79. (Amended) The nucleic acid molecule of claim 75 that further comprises a nucleotide sequence heterologous to the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810.

D6 95. (Amended) The nucleic acid molecule of claim 88 further comprising a nucleotide sequence heterologous to SEQ ID NO:1.

D7 109. (Amended) The nucleic acid molecule of claim 104 further comprising a nucleotide sequence heterologous to said cDNA clone.

291. (Amended) An isolated polynucleotide comprising a nucleotide sequence that is at least 95% identical to a nucleotide sequence encoding amino acid residues 31-300 of SEQ ID NO:2 wherein said polynucleotide encodes a polypeptide that binds Fas ligand.

D8 292. (Amended) An isolated polynucleotide comprising a nucleotide sequence that is at least 95% identical to a nucleotide sequence encoding amino acid residues 31-283 of SEQ ID NO: 2 wherein said polynucleotide encodes a polypeptide that binds Fas ligand.

D9 302. (Amended) An expression vector for the production of a polypeptide comprising amino acids 31-300 of SEQ ID NO:2 comprising a polynucleotide that encodes amino acids 31-300 of SEQ ID NO:2 operably associated with a regulatory element that controls expression of said polynucleotide.

D10 304. (Amended) A method of for producing a polypeptide comprising amino acids 31-300 of SEQ ID NO:2, comprising culturing the host cell of claim 303 under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.

305. (Amended) A process for producing a cell which produces a polypeptide comprising amino acids 31-300 of SEQ ID NO:2, comprising transforming or transfecting a host cell with the expression vector of claim 302 such that the host cell, under appropriate culture conditions, produces said polypeptide.